Summary：**BIO Asia‑Taiwan 2026 Unites 60 Nations, Inspiring Taiwan’s Biotech Breakthroughs** *TAIPEI, July

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**BIO Asia‑Taiwan 2026 Unites 60 Nations, Inspiring Taiwan’s Biotech Breakthroughs**
*TAIPEI, July 21, 2026 /PRNewswire/* – BIO Asia–Taiwan 2026, the continent’s premier biotechnology forum co‑hosted by the Taiwan Bio Industry Organization (Taiwan BIO) and the global Biotechnology Innovation Organization (BIO), wrapped up on July 19 after three days of intensive dialogue, deal‑making and showcase sessions. Delegates from sixty countries gathered in Taipei’s Nangang Exhibition Center, underscoring the event’s growing stature as a catalyst for cross‑border collaboration in life sciences.

### Introduction
The conference opened with a keynote address from Taiwan’s Minister of Economic Affairs, who highlighted the island’s strategic push to become a hub for advanced therapeutics, precision agriculture and digital health. Over 1,200 participants—including CEOs of multinational pharma firms, academic leaders, venture capitalists and government officials—attended plenary panels, technical workshops and a sprawling exhibition floor featuring more than 250 biotech start‑ups.

### Key Developments
Several announcements dominated the agenda. Taiwan BIO unveiled a NT$5 billion fund aimed at accelerating early‑stage gene‑editing projects, while BIO announced a new partnership program that will grant Taiwanese start‑ups streamlined access to U.S. regulatory pathways. Notable breakthroughs presented included a CRISPR‑based therapy for hereditary retinal disease developed by National Taiwan University Hospital, a plant‑derived vaccine platform showcased by a Taipei‑based agri‑biotech firm, and an AI‑driven drug‑screening tool that cut lead‑identification time by 40 %. Over 150 memoranda of understanding were signed,